Skip to content

Study evaluating the efficacy of unani formulation in Gastritis caused by H. pylori

A Comparative Randomized clinical Study to evaluate the efficacy of Unani formulation in H. pylori Gastritis - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/07/113391
Enrollment
120
Registered
2026-07-06
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K259- Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: Unani formulation: Unani formulation constituted by Zanjabeel (Zingiber officinale) + Badiyan (Foeniculum vulgare) + Hilteet ( Ferula asafoetida) in the ratio of 2:1:3 Control Intervent

Sponsors

Department of Jarahat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: patients of age 14 year or above irrespective of gender H. pylori induced gastritis patients diagnosed on endoscopy using Rapid urease test kit culture & sensitivity and histopathology Patient given written consent

Exclusion criteria

Exclusion criteria: Patient of age below 14 years Pregnant and lactating mothers Patient sensitive to any of the test or standard drugs included in the study will be excluded along with appropriate treatment, as and when required Participants with severe comorbidities such as diabetes advanced malignancies severe cardiac hepatic and renal diseases TB acute or chronic ulcerative positive cases of venereal disease HIV & HBsAg positive cases Known allergies or intolerances to medications used for the treatment of upper GI inflammatory conditions or H. pylori eradication Already taken H. pylori kit

Design outcomes

Primary

MeasureTime frame
Eradication of H. pylori with healing of the gastric mucosa endoscopyTimepoint: Assessment at day 0 and day 90

Secondary

MeasureTime frame
Relief in symptom Dyspepsia Pain abdomen Flatulence Nausea or vomiting Timepoint: Assessment at day 0 and day 90

Countries

India

Contacts

Public ContactTaqdees Fatima

Ajmal Khan Tibbiya College, Faculty of Unani Medicine AMU Aligarh

tafseerali@gmail.com7017474312

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026